Also Known as Ovitrelle
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Ovidrel is a recombinant human chorionic gonadotropin (r-hCG) used to induce final follicular maturation and ovulation in women undergoing assisted reproductive technologies (ART), such as in vitro fertilization (IVF), or for ovulation induction in women with anovulation or oligo-ovulation. It mimics the natural luteinizing hormone (LH) surge, promoting the release of a mature oocyte from the follicle. Ovidrel is also used in fertility protocols to support luteal phase function. It is manufactured using recombinant DNA technology, ensuring high purity and consistency.
Fact Table | |
Formula | C1001H1573N273O336S26 (approximate, glycoprotein) |
License | US FDA; EMA |
Bioavailability | ~40% (subcutaneous) |
Legal status | Prescription only |
Chemical Name | Recombinant human chorionic gonadotropin (choriogonadotropin alfa) |
Elimination half-life | ~30 hours (subcutaneous) |
Dosage (Strength) | 250 mcg prefilled syringe (subcutaneous injection) |
Pregnancy | Category C – not for use during established pregnancy |
Brands | Ovidrel |
Protein binding | Not well characterized (glycoprotein hormone) |
PubChem CID | 16133278 |
MedlinePlus | a601012 |
ChEBI | CHEBI:37733 |
ATC code | G03GA08 |
DrugBank | DB00011 |
KEGG | D06400 |
Routes of administration | Subcutaneous injection |
Ovidrel is administered by subcutaneous injection in a single fixed dose:
Use under the supervision of a fertility specialist. Proper injection technique and timing are critical for treatment success.
Each prefilled syringe of Ovidrel contains:
Ovidrel is supplied in a pre-filled, single-use, 0.5 mL syringe for subcutaneous administration.
Ovidrel is contraindicated in patients with:
Ovidrel should be used only in appropriately selected patients. The most significant risk is ovarian hyperstimulation syndrome (OHSS), which can be serious or life-threatening. Monitor for abdominal pain, weight gain, and ascites post-injection. Use caution in women with PCOS, as they are at higher risk for OHSS and multiple gestations. Carefully monitor ovarian response via ultrasound and estradiol levels. Discontinue gonadotropins if excessive response occurs. Ovidrel does not support implantation or ongoing pregnancy—additional hormonal support may be required.
Common and potential side effects include: